Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

MERTK (c-mer proto-oncogene tyrosine kinase)

Written2008-11Amy K Keating, Rachel MA Linger, Doug K Graham
Department of Pediatrics, University of Colorado at Denver, Health Sciences Center, Aurora, CO, USA

(Note : for Links provided by Atlas : click)


Alias_namesc-mer proto-oncogene tyrosine kinase
Alias_symbol (synonym)mer
Other aliasC-mer
Eyk (chicken)
Tyro-12 (rat)
LocusID (NCBI) 10461
Atlas_Id 41339
Location 2q13  [Link to chromosome band 2q13]
Location_base_pair Starts at 112656191 and ends at 112786945 bp from pter ( according to hg19-Feb_2009)  [Mapping MERTK.png]
Fusion genes
(updated 2016)
MERTK (2q13) / MERTK (2q13)MERTK (2q13) / SHISA5 (3p21.31)PLXNB2 (22q13.33) / MERTK (2q13)
RBM14 (11q13.2) / MERTK (2q13)SOX13 (1q32.1) / MERTK (2q13)TMEM87B (2q13) / MERTK (2q13)


  DNA structure of the MERTK gene aligned with the corresponding functional protein domains. The open ended boxes for exons 1 and 19 indicate untranslated regions which are not depicted here.
Description The human MERTK gene is located on chromosome 2q14.1 and contains 19 exons. Exons 1-9 encode the extracellular domain, exon 10 encodes the transmembrane domain, and exons 11-19 encode the intracellular domain. Within the extracellular domain, two immunoglobulin (Ig) domains and two fibronectin type III (FNIII) domains are present. The Ig domains are encoded by exons 2-5 and the FNIII domains are encoded by exons 6-9. Within the intracellular region, exons 13-19 encode the tyrosine kinase domain (Gal et al., 2000).
Transcription Tissue analysis of MERTK expression has demonstrated a 4.4 kilobase message in a spectrum of tissues including the testis, ovary, prostate, lung, kidney, spleen, placenta, thymus, small intestine, colon, and liver. A larger transcript (approximately 5.5 to 6.5 kilobase message) has been detected in testis and ovary. A potential alternatively spliced transcript is generated by the insertion of a novel exon between exons 7 and exon 8. This alternative transcript may encode a soluble MERTK (Graham et al., 1994).


  The diagram above depicts the domain structure of the Mer receptor tyrosine kinase protein. The conserved sequence within the kinase domain is depicted. The diagram below depicts the domain structure of the ligands, Gas6 and Protein S. Gas6 and Protein S have the same domain structure with the exception of thrombin cleavage sites which are present in the loop region of Protein S but not Gas6. Vitamin-K dependent carboxylation of the Gamma-carboxyglutamic acid (Gla) domain is required for biologic activity of these ligands. The crystal structure of a Gas6/Axl complex suggests that the laminin G-like (LG) domains mediate binding to the Ig-like domains of MERTK.
Description The MERTK receptor is synthesized as a protein containing 999 amino acids. Although the predicted molecular weight of MERTK is approximately 110 kD, the extracellular domain of MERTK possesses sites for NH2-linked glycosylation and the mature, fully glycosylated form of MERTK is approximately 205 kD (Sather et al., 2007). Depending on the cell type, underglycosylated forms of MERTK protein may also be produced leading to a range in MERTK protein sizes from 160 to 205 kD. The extracellular component of the MERTK receptor encodes two Ig domains (aa 112-186 for domain 1 and aa 197-280 for domain 2) and two FNIII domains (aa 284-378 for domain 1 and 386-478 for domain 2). The two Ig domains and two FNIII domains define MERTK as part of a family of receptor tyrosine kinases (RTKs) which contains only two other members, AXL and Tyro-3. Together, Tyro-3, Axl, and Mer constitute the TAM family of receptor tyrosine kinases (Linger et al., 2008). The extracellular domain of MERTK serves as the ligand binding region for the ligands GAS6 (Chen et al., 1997) and Protein S (Prasad et al., 2006). Specifically, Gas6 has been shown to bind TAM receptors in the immunologlobulin domains (Sasaki et al., 2006).
The intracellular component of the MERTK receptor includes the tyrosine kinase domain (aa 600-848). Within this tyrosine kinase domain is a signature motif, KWIAIES, which is only found in the TAM receptor tyrosine kinases (Graham et al., 1994). Following ligand binding to the extracellular domain, MERTK receptor dimerization and tyrosine autophosphorylation occurs. Three tyrosine residues (Y749, Y753, and Y754) within the activation loop of the kinase domain have been identified as the primary sites of autophosphorylation (Ling et al., 1996). These three residues are also conserved in the same sequence context in Axl and Tyro-3. Another residue within the kinase domain, Y872, is part of consensus GRB2 binding site, YXNX, and the corresponding sequence in murine MERTK has been shown to bind Grb2, recruit and activate PI3K as well as transcriptionally activate NF-kB (Georgescu et al., 1999). Phosphorylation and activation of PLCgamma may occur through direct binding of one of its SH2 domains to endogenous phospho-MERTK (Sen et al., 2007). Similarly, there is evidence that PI3K may interact with MERTK via a SH2 domain (Sen et al., 2007). Finally, VAV1 has been shown to constitutively interact with MERTK, and the release of VAV1 upon ligand-dependent MERTK activation leads to activation of Rho family members (Mahajan et al., 2003).
The extracellular domain of MERTK is also constitutively shed via cleavage due to a metalloproteinase. The resulting soluble MERTK consists of both Ig domains and both FNIII domains, and is believed to function as a decoy receptor for MERTK ligands (Sather et al., 2007).
Expression Within hematopoietic lineages, MERTK is expressed in macrophages, dendritic cells, NK cells, NKT cells, megakaryocytes, and platelets (Graham et al., 1994; Angelillo-Scherrer et al., 2001; Behrens et al., 2003). High levels of MERTK expression are also detected in ovary, prostate, testis, lung, retina, and kidney. Lower levels of Mer are found in heart, brain, and skeletal muscle (Graham et al., 1994). Upregulation or ectopic Mer expression is found in a spectrum of malignant cells (Linger et al., 2008).
Localisation MERTK is a transmembrane receptor tyrosine kinase.
Function The activation of MERTK and downstream signaling via PI3K/Akt, PLCGamma, VAV1, and MAPK/ERK are thought to mediate MERTK's cellular functions in cell survival, proinflammatory cytokine production, and actin reorganization/cell migration. Overexpression or ectopic expression of MERTK has been implicated in oncogenesis (Linger et al., 2008).
Homology The two Ig domains and two FNIII domains are shared with Axl and Tyro-3, the other two members of the TAM RTK family. The protein sequences of TAM receptors are 31-36% identical (52-57% similar) in the extracellular regions. The intracellular domains share 54-59% sequence identity (72-75% similarity) with higher homology in the tyrosine kinase domain (Graham et al., 1995).


Germinal Germline mutations in the second exon of MERTK are well characterized and lead to retinitis pigmentosa and retinal dystrophy. The first description of this mutation was in the Royal College of Surgeon (RCS) rat and details a deletion that leads to a frameshift and early translation termination codon, resulting in an aberrant non-functional protein product (D'Cruz et al., 2000). A similar retinal dystrophy phenotype is found in the merkd mouse, which contains a targeted disruption of the MERTK gene (Duncan et al., 2003). In humans several different mutations that affect the MERTK region have been described in individuals suffering from retinal dystrophy.

Implicated in

Entity Retinitis pigmentosa and retinal dystrophy
Disease Retinitis pigementosa is a disorder that affects 1 in 3500 people and stems from loss of functional photoreceptor cells in the retina, and eventual visual loss. Loss of functional MERTK protein leads to ineffective phagocytosis and clearance of apoptotic cells, with resultant buildup of the retinal pigmented epithelium leading to visual loss and is one known genetic cause of retinal dystrophy (Shuster et al., 1990; Gal et al., 2000; Tada et al., 2006; Tschernutter et al., 2006).
Entity Malignancy
Disease MERTK and its family members have been implicated in a number of malignant conditions. MERTK is not expressed on the normal lymphocytes but has been found to be expressed in a majority of lymphoblasts from patients with T-cell leukemia, certain subsets of B-cell leukemia, and mantle cell lymphoma (Yeoh et al., 2002; Graham et al., 2006). Forced overexpression of MERTK in a murine model leads to T-cell leukemia and lymphoma (Keating et al., 2006). MERTK has also been associated with a variety of other non-hematologic malignancies including: glioblastoma multiforme (Ling et al., 1995), gastric cancer (Wu et al., 2002), and prostate cancer (Mahajan et al., 2005). MERTK is known to play a role in several oncogenic mechanisms, including angiogenesis, migration and invasion, and cell survival signaling as reviewed in Linger et al (2008).
Entity Autoimmune Disease
Disease Animal models that lack functional MERTK protein have macrophages that are unable to appropriately engulf apoptotic cells. This inefficient clearance of dead cells can lead to activation of inflammation and development of autoimmunity (Scott et al., 2001). This mechanism has been suggested for systemic lupus erythematosis, but no human cases have been reported.


Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis.
Angelillo-Scherrer A, de Frutos P, Aparicio C, Melis E, Savi P, Lupu F, Arnout J, Dewerchin M, Hoylaerts M, Herbert J, Collen D, Dahlback B, Carmeliet P.
Nat Med. 2001 Feb;7(2):215-21.
PMID 11175853
The mer receptor tyrosine kinase: expression and function suggest a role in innate immunity.
Behrens EM, Gadue P, Gong SY, Garrett S, Stein PL, Cohen PL.
Eur J Immunol. 2003 Aug;33(8):2160-7.
PMID 12884290
Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation.
Chen J, Carey K, Godowski PJ.
Oncogene. 1997 May 1;14(17):2033-9.
PMID 9160883
Mutation of the receptor tyrosine kinase gene Mertk in the retinal dystrophic RCS rat.
D'Cruz PM, Yasumura D, Weir J, Matthes MT, Abderrahim H, LaVail MM, Vollrath D.
Hum Mol Genet. 2000 Mar 1;9(4):645-51.
PMID 10699188
An RCS-like retinal dystrophy phenotype in mer knockout mice.
Duncan JL, LaVail MM, Yasumura D, Matthes MT, Yang H, Trautmann N, Chappelow AV, Feng W, Earp HS, Matsushima GK, Vollrath D.
Invest Ophthalmol Vis Sci. 2003 Feb;44(2):826-38.
PMID 12556419
Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa.
Gal A, Li Y, Thompson DA, Weir J, Orth U, Jacobson SG, Apfelstedt-Sylla E, Vollrath D.
Nat Genet. 2000 Nov;26(3):270-1.
PMID 11062461
Biological effects of c-Mer receptor tyrosine kinase in hematopoietic cells depend on the Grb2 binding site in the receptor and activation of NF-kappaB.
Georgescu MM, Kirsch KH, Shishido T, Zong C, Hanafusa H.
Mol Cell Biol. 1999 Feb;19(2):1171-81.
PMID 9891051
Cloning and developmental expression analysis of the murine c-mer tyrosine kinase.
Graham DK, Bowman GW, Dawson TL, Stanford WL, Earp HS, Snodgrass HR.
Oncogene. 1995 Jun 15;10(12):2349-59.
PMID 7784083
Cloning and mRNA expression analysis of a novel human protooncogene, c-mer.
Graham DK, Dawson TL, Mullaney DL, Snodgrass HR, Earp HS.
Cell Growth Differ. 1994 Jun;5(6):647-57.
PMID 8086340
Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia.
Graham DK, Salzberg DB, Kurtzberg J, Sather S, Matsushima GK, Keating AK, Liang X, Lovell MA, Williams SA, Dawson TL, Schell MJ, Anwar AA, Snodgrass HR, Earp HS.
Clin Cancer Res 2006; 12: 2662-9.
PMID 16675557
Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase.
Keating AK, Salzberg DB, Sather S, Liang X, Nickoloff S, Anwar A, Deryckere D, Hill K, Joung D, Sawczyn KK, Park J, Curran-Everett D, McGavran L, Meltesen L, Gore L, Johnson GL, Graham DK.
Oncogene. 2006 Oct 5;25(45):6092-100. Epub 2006 May 1.
PMID 16652142
Mitogenic signals and transforming potential of Nyk, a newly identified neural cell adhesion molecule-related receptor tyrosine kinase.
Ling L, Kung HJ.
Mol Cell Biol. 1995 Dec;15(12):6582-92.
PMID 8524223
Identification of the major autophosphorylation sites of Nyk/Mer, an NCAM-related receptor tyrosine kinase.
Ling L, Templeton D, Kung HJ.
J Biol Chem. 1996 Aug 2;271(31):18355-62.
PMID 8702477
TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer.
Linger RM, Keating AK, Earp HS, Graham DK.
Adv Cancer Res. 2008;100:35-83.
PMID 18620092
Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox.
Mahajan NP, Whang YE, Mohler JL, Earp HS.
Cancer Res. 2005 Nov 15;65(22):10514-23.
PMID 16288044
TAM receptor function in the retinal pigment epithelium.
Prasad D, Rothlin CV, Burrola P, Burstyn-Cohen T, Lu Q, Garcia de Frutos P, Lemke G.
Mol Cell Neurosci. 2006 Sep;33(1):96-108. Epub 2006 Aug 9.
PMID 16901715
Structural basis for Gas6-Axl signalling.
Sasaki T, Knyazev PG, Clout NJ, Cheburkin Y, Gohring W, Ullrich A, Timpl R, Hohenester E.
EMBO J. 2006 Jan 11;25(1):80-7. Epub 2005 Dec 15.
PMID 16362042
A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation.
Sather S, Kenyon KD, Lefkowitz JB, Liang X, Varnum BC, Henson PM, Graham DK.
Blood. 2007 Feb 1;109(3):1026-33. Epub 2006 Oct 17.
PMID 17047157
Phagocytosis and clearance of apoptotic cells is mediated by MER.
Scott RS, McMahon EJ, Pop SM, Reap EA, Caricchio R, Cohen PL, Earp HS, Matsushima GK.
Nature. 2001 May 10;411(6834):207-11.
PMID 11346799
Apoptotic cells induce Mer tyrosine kinase-dependent blockade of NF-kappaB activation in dendritic cells.
Sen P, Wallet MA, Yi Z, Huang Y, Henderson M, Mathews CE, Earp HS, Matsushima G, Baldwin AS Jr, Tisch RM.
Blood. 2007 Jan 15;109(2):653-60. Epub 2006 Sep 28.
PMID 17008547
Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Shuster JJ, Falletta JM, Pullen DJ, Crist WM, Humphrey GB, Dowell BL, Wharam MD, Borowitz M.
Blood. 1990 Jan 1;75(1):166-73.
PMID 1688495
Screening of the MERTK gene for mutations in Japanese patients with autosomal recessive retinitis pigmentosa.
Tada A, Wada Y, Sato H, Itabashi T, Kawamura M, Tamai M, Nishida K.
Mol Vis. 2006 May 9;12:441-4.
PMID 16710167
Clinical characterisation of a family with retinal dystrophy caused by mutation in the Mertk gene.
Tschernutter M, Jenkins SA, Waseem NH, Saihan Z, Holder GE, Bird AC, Bhattacharya SS, Ali RR, Webster AR.
Br J Ophthalmol. 2006 Jun;90(6):718-23.
PMID 16714263
Clinical significance of AXL kinase family in gastric cancer.
Wu CW, Li AF, Chi CW, Lai CH, Huang CL, Lo SS, Lui WY, Lin WC.
Anticancer Res. 2002 Mar-Apr;22(2B):1071-8.
PMID 12168903
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.
Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, Behm FG, Raimondi SC, Relling MV, Patel A, Cheng C, Campana D, Wilkins D, Zhou X, Li J, Liu H, Pui CH, Evans WE, Naeve C, Wong L, Downing JR.
Cancer Cell. 2002 Mar;1(2):133-43.
PMID 12086872


This paper should be referenced as such :
Keating, AK ; Linger, RMA ; Graham, DK
MERTK (c-mer proto-oncogene tyrosine kinase)
Atlas Genet Cytogenet Oncol Haematol. 2009;13(10):728-732.
Free journal version : [ pdf ]   [ DOI ]
On line version :

External links

HGNC (Hugo)MERTK   7027
Entrez_Gene (NCBI)MERTK  10461  MER proto-oncogene, tyrosine kinase
AliasesMER; RP38; Tyro12; c-Eyk; 
GeneCards (Weizmann)MERTK
Ensembl hg19 (Hinxton)ENSG00000153208 [Gene_View]  chr2:112656191-112786945 [Contig_View]  MERTK [Vega]
Ensembl hg38 (Hinxton)ENSG00000153208 [Gene_View]  chr2:112656191-112786945 [Contig_View]  MERTK [Vega]
ICGC DataPortalENSG00000153208
Genatlas (Paris)MERTK
Genetics Home Reference (NIH)MERTK
Genomic and cartography
GoldenPath hg19 (UCSC)MERTK  -     chr2:112656191-112786945 +  2q14.1   [Description]    (hg19-Feb_2009)
GoldenPath hg38 (UCSC)MERTK  -     2q14.1   [Description]    (hg38-Dec_2013)
EnsemblMERTK - 2q14.1 [CytoView hg19]  MERTK - 2q14.1 [CytoView hg38]
Mapping of homologs : NCBIMERTK [Mapview hg19]  MERTK [Mapview hg38]
OMIM604705   613862   
Gene and transcription
Genbank (Entrez)AK026681 AK294196 AK308695 AK316584 AL705756
RefSeq transcript (Entrez)NM_006343
RefSeq genomic (Entrez)NC_000002 NC_018913 NG_011607 NT_005403 NW_004929304
Consensus coding sequences : CCDS (NCBI)MERTK
Cluster EST : UnigeneHs.306178 [ NCBI ]
CGAP (NCI)Hs.306178
Alternative Splicing GalleryENSG00000153208
Gene Expression Viewer (FireBrowse)MERTK [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevisibleExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)10461
GTEX Portal (Tissue expression)MERTK
Protein : pattern, domain, 3D structure
UniProt/SwissProtQ12866   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtQ12866  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProQ12866
Splice isoforms : SwissVarQ12866
Catalytic activity : Enzyme2.7.10.1 [ Enzyme-Expasy ] [ IntEnz-EBI ] [ BRENDA ] [ KEGG ]   
Domaine pattern : Prosite (Expaxy)FN3 (PS50853)    IG_LIKE (PS50835)    PROTEIN_KINASE_ATP (PS00107)    PROTEIN_KINASE_DOM (PS50011)    PROTEIN_KINASE_TYR (PS00109)   
Domains : Interpro (EBI)FN3_dom    Ig-like_dom    Ig-like_fold    Ig_sub    Immunoglobulin    Kinase-like_dom    Prot_kinase_dom    Protein_kinase_ATP_BS    Ser-Thr/Tyr_kinase_cat_dom    Tyr_kinase_AS    Tyr_kinase_cat_dom   
Domain families : Pfam (Sanger)fn3 (PF00041)    ig (PF00047)    Pkinase_Tyr (PF07714)   
Domain families : Pfam (NCBI)pfam00041    pfam00047    pfam07714   
Domain families : Smart (EMBL)FN3 (SM00060)  IG (SM00409)  TyrKc (SM00219)  
Conserved Domain (NCBI)MERTK
DMDM Disease mutations10461
Blocks (Seattle)MERTK
PDB (SRS)2DBJ    2P0C    3BPR    3BRB    3TCP    4M3Q    4MH7    4MHA   
PDB (PDBSum)2DBJ    2P0C    3BPR    3BRB    3TCP    4M3Q    4MH7    4MHA   
PDB (IMB)2DBJ    2P0C    3BPR    3BRB    3TCP    4M3Q    4MH7    4MHA   
PDB (RSDB)2DBJ    2P0C    3BPR    3BRB    3TCP    4M3Q    4MH7    4MHA   
Structural Biology KnowledgeBase2DBJ    2P0C    3BPR    3BRB    3TCP    4M3Q    4MH7    4MHA   
SCOP (Structural Classification of Proteins)2DBJ    2P0C    3BPR    3BRB    3TCP    4M3Q    4MH7    4MHA   
CATH (Classification of proteins structures)2DBJ    2P0C    3BPR    3BRB    3TCP    4M3Q    4MH7    4MHA   
Human Protein AtlasENSG00000153208
Peptide AtlasQ12866
IPIIPI00029756   IPI00873918   IPI00917839   IPI00917977   IPI00915893   
Protein Interaction databases
IntAct (EBI)Q12866
Ontologies - Pathways
Ontology : AmiGOphotoreceptor outer segment  natural killer cell differentiation  transmembrane receptor protein tyrosine kinase activity  protein binding  ATP binding  extracellular space  cytoplasm  plasma membrane  integral component of plasma membrane  protein phosphorylation  phagocytosis  cell surface receptor signaling pathway  cell-cell signaling  spermatogenesis  rhabdomere  peptidyl-tyrosine phosphorylation  peptidyl-tyrosine phosphorylation  platelet activation  secretion by cell  substrate adhesion-dependent cell spreading  apoptotic cell clearance  protein kinase B signaling  positive regulation of phagocytosis  leukocyte migration  negative regulation of lymphocyte activation  retina development in camera-type eye  vagina development  negative regulation of leukocyte apoptotic process  
Ontology : EGO-EBIphotoreceptor outer segment  natural killer cell differentiation  transmembrane receptor protein tyrosine kinase activity  protein binding  ATP binding  extracellular space  cytoplasm  plasma membrane  integral component of plasma membrane  protein phosphorylation  phagocytosis  cell surface receptor signaling pathway  cell-cell signaling  spermatogenesis  rhabdomere  peptidyl-tyrosine phosphorylation  peptidyl-tyrosine phosphorylation  platelet activation  secretion by cell  substrate adhesion-dependent cell spreading  apoptotic cell clearance  protein kinase B signaling  positive regulation of phagocytosis  leukocyte migration  negative regulation of lymphocyte activation  retina development in camera-type eye  vagina development  negative regulation of leukocyte apoptotic process  
REACTOMEQ12866 [protein]
REACTOME Pathways202733 [pathway]   
Atlas of Cancer Signalling NetworkMERTK
Wikipedia pathwaysMERTK
Orthology - Evolution
GeneTree (enSembl)ENSG00000153208
Phylogenetic Trees/Animal Genes : TreeFamMERTK
Homologs : HomoloGeneMERTK
Homology/Alignments : Family Browser (UCSC)MERTK
Gene fusions - Rearrangements
Fusion : MitelmanRBM14/MERTK [11q13.2/2q13]  [t(2;11)(q13;q13)]  
Fusion : MitelmanSOX13/MERTK [1q32.1/2q13]  [t(1;2)(q32;q13)]  
Fusion: TCGASOX13 1q32.1 MERTK 2q13 BRCA
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerMERTK [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)MERTK
Exome Variant ServerMERTK
ExAC (Exome Aggregation Consortium)MERTK (select the gene name)
Genetic variants : HAPMAP10461
Genomic Variants (DGV)MERTK [DGVbeta]
DECIPHER (Syndromes)2:112656191-112786945  ENSG00000153208
CONAN: Copy Number AnalysisMERTK 
ICGC Data PortalMERTK 
TCGA Data PortalMERTK 
Broad Tumor PortalMERTK
OASIS PortalMERTK [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICMERTK  [overview]  [genome browser]  [tissue]  [distribution]  
Mutations and Diseases : HGMDMERTK
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
LOVD (Leiden Open Variation Database)Eye diseases - LOVD
BioMutasearch MERTK
DgiDB (Drug Gene Interaction Database)MERTK
DoCM (Curated mutations)MERTK (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)MERTK (select a term)
NCG5 (London)MERTK
Cancer3DMERTK(select the gene name)
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
OMIM604705    613862   
Genetic Testing Registry MERTK
NextProtQ12866 [Medical]
Huge Navigator MERTK [HugePedia]
snp3D : Map Gene to Disease10461
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD10461
Chemical/Pharm GKB GenePA30759
Clinical trialMERTK
canSAR (ICR)MERTK (select the gene name)
PubMed95 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Wed Apr 12 11:35:00 CEST 2017

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us